These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11576359)

  • 41. Lipid formulations of amphotericin B.
    Dix SP; Andriole VT
    Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Faucher C; Fürst S; Duran S; Berger P; Vey N; Stoppa AM; Bouabdallah R; Gastaut JA; Viens P; Blaise D; Mohty M
    Bone Marrow Transplant; 2007 Mar; 39(5):301-6. PubMed ID: 17262059
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanisms and management of amphotericin B-induced nephrotoxicity.
    Miano-Mason TM
    Cancer Pract; 1997; 5(3):176-81. PubMed ID: 9171554
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention of amphotericin-B-induced nephrotoxicity by loading with sodium chloride: a report of 1291 days of treatment with amphotericin B without renal failure.
    Arning M; Scharf RE
    Klin Wochenschr; 1989 Oct; 67(20):1020-8. PubMed ID: 2586007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis.
    Shah S; Vervan M
    Am J Health Syst Pharm; 2005 Apr; 62(7):720-5. PubMed ID: 15790799
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transient asystole associated with amphotericin B infusion.
    DeMonaco HJ; McGovern B
    Drug Intell Clin Pharm; 1983; 17(7-8):547-8. PubMed ID: 6347598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys.
    Bullock WE; Luke RG; Nuttall CE; Bhathena D
    Antimicrob Agents Chemother; 1976 Sep; 10(3):555-63. PubMed ID: 791105
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk factors of ventricular fibrillation during rapid amphotericin B infusion.
    Craven PC; Gremillion DH
    Antimicrob Agents Chemother; 1985 May; 27(5):868-71. PubMed ID: 4015077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neonatal renal failure due to obstructive candidal bezoars.
    Hari P; Srivastava A; Gupta AK; Srivastava RN
    Pediatr Nephrol; 1997 Aug; 11(4):497-8. PubMed ID: 9260255
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Critical issues in nephrology.
    Peixoto AJ
    Clin Chest Med; 2003 Dec; 24(4):561-81. PubMed ID: 14710691
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessing the guidelines for potassium replacement in pediatric oncology patients receiving amphotericin B.
    Lafreniere JA; Hamilton DP; Carr RR
    J Pediatr Pharmacol Ther; 2006 Oct; 11(4):223-32. PubMed ID: 23115538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy.
    Harbarth S; Pestotnik SL; Lloyd JF; Burke JP; Samore MH
    Am J Med; 2001 Nov; 111(7):528-34. PubMed ID: 11705428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amphotericin B formulations: a comparative review of efficacy and toxicity.
    Hamill RJ
    Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Amphotericin B nephrotoxicity.
    Sabra R; Branch RA
    Drug Saf; 1990; 5(2):94-108. PubMed ID: 2182052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute kidney injury in a child treated with cisplatin and amphotericin B.
    Skajaa T; Faerch M; Hasle H
    Cancer Chemother Pharmacol; 2024 Oct; 94(4):623-626. PubMed ID: 39110201
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic drug monitoring of liposomal amphotericin B in children. Are we there yet? A systematic review.
    Lai T; Yeo CY; Rockliff B; Stokes M; Kim HY; Marais BJ; McLachlan AJ; Alffenaar JC
    J Antimicrob Chemother; 2024 Apr; 79(4):703-711. PubMed ID: 38252921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The dose of the normal saline pre-infusion and other risk factors for amphotericin B deoxycholate-associated acute kidney injury.
    Virojanawat M; Tungsanga S; Paitoonpong L; Katavetin P
    Asian Biomed (Res Rev News); 2023 Dec; 17(6):281-286. PubMed ID: 38161348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single High Dose of Liposomal Amphotericin B in Human Immunodeficiency Virus/AIDS-Related Disseminated Histoplasmosis: A Randomized Trial.
    Pasqualotto AC; Lana DD; Godoy CSM; Leitão TDMJS; Bay MB; Damasceno LS; Soares RBA; Kist R; Silva LR; Wiltgen D; Melo M; Guimarães TF; Guimarães MR; Vechi HT; de Mesquita JRL; Monteiro GRG; Adenis A; Bahr NC; Spec A; Boulware DR; Israelski D; Chiller T; Falci DR
    Clin Infect Dis; 2023 Oct; 77(8):1126-1132. PubMed ID: 37232940
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful treatment of invasive tracheobronchial pulmonary aspergillosis with venovenous extracorporeal membrane oxygenation and combined systemic, intratracheal instillation of liposomal amphotericin B: a case report.
    Sato S; Kamata W; Fukaguchi K; Tsunoda S; Kamio T; Koyama H; Sugimoto H; Tamai Y
    J Med Case Rep; 2022 Dec; 16(1):470. PubMed ID: 36536458
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.